Certain Common Stock of Benitec Biopharma Inc. are subject to a Lock-Up Agreement Ending on 6-NOV-2023.

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).